Oppenheimer Affirms Outperform Rating for Ventyx Biosciences
Nov 8, 2024
Biosciences Investment Portfolios
Ventyx Biosciences Faces Setback as Crohn's Disease Drug Candidate VTX958 Fails Phase 2 Trial
Jul 29, 2024
Cellectar Biosciences Prepares Key Opinion Leader Event for CLOVER WaM Trial Analysis
Jun 28, 2024
Enveric Biosciences Reveals Decline in Revenue for Q3 2023 Amid Advancements of Psychedelics into Clinical Trials
Nov 15, 2023